1. Home
  2. VRAX vs EVAX Comparison

VRAX vs EVAX Comparison

Compare VRAX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • EVAX
  • Stock Information
  • Founded
  • VRAX 2013
  • EVAX 2008
  • Country
  • VRAX United Kingdom
  • EVAX Denmark
  • Employees
  • VRAX N/A
  • EVAX N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VRAX Health Care
  • EVAX Health Care
  • Exchange
  • VRAX Nasdaq
  • EVAX Nasdaq
  • Market Cap
  • VRAX 7.3M
  • EVAX 8.7M
  • IPO Year
  • VRAX 2022
  • EVAX 2021
  • Fundamental
  • Price
  • VRAX $1.90
  • EVAX $2.49
  • Analyst Decision
  • VRAX
  • EVAX Strong Buy
  • Analyst Count
  • VRAX 0
  • EVAX 3
  • Target Price
  • VRAX N/A
  • EVAX $33.33
  • AVG Volume (30 Days)
  • VRAX 282.7K
  • EVAX 6.9M
  • Earning Date
  • VRAX 02-05-2025
  • EVAX 03-26-2025
  • Dividend Yield
  • VRAX N/A
  • EVAX N/A
  • EPS Growth
  • VRAX N/A
  • EVAX N/A
  • EPS
  • VRAX N/A
  • EVAX N/A
  • Revenue
  • VRAX $84,872.00
  • EVAX $3,295,000.00
  • Revenue This Year
  • VRAX $5,169.18
  • EVAX $9,039.73
  • Revenue Next Year
  • VRAX $66.97
  • EVAX $1.47
  • P/E Ratio
  • VRAX N/A
  • EVAX N/A
  • Revenue Growth
  • VRAX 7.03
  • EVAX N/A
  • 52 Week Low
  • VRAX $0.60
  • EVAX $2.22
  • 52 Week High
  • VRAX $9.00
  • EVAX $22.50
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 49.13
  • EVAX 39.85
  • Support Level
  • VRAX $1.58
  • EVAX $2.30
  • Resistance Level
  • VRAX $2.10
  • EVAX $2.80
  • Average True Range (ATR)
  • VRAX 0.25
  • EVAX 0.51
  • MACD
  • VRAX 0.01
  • EVAX 0.03
  • Stochastic Oscillator
  • VRAX 47.88
  • EVAX 6.97

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About EVAX Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

Share on Social Networks: